NCT00979004终止2 期
A Phase 2, Multi-Center, Single-Blind, Placebo-Controlled Pharmacodynamic Evaluation of ICA-105665 in Epilepsy Patients With a Photo-Induced Paroxysmal EEG Response
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Pfizer
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Change in photosensitivity response
研究概览
简要总结
Subjects with epilepsy with a documented photoparoxysmal response to intermittent photic stimulation (IPS) will participate. Four subjects will be enrolled at each dose level and will receive a single dose of placebo and a single dose of ICA-105665 during the study, each followed by intermittent photic stimulation. The effects of ICA-105665 on the photoparoxysmal electroencephalography (EEG) response of each group will be reviewed before the dose is selected for each subsequent group of subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis and history of epilepsy for which they are on 0-2 concurrent antiepileptic drugs.
- •On a stable dose of their current AED(s) for 4 weeks prior to the Screening Visit.
- •Must be in good health (with the exception of epilepsy), as determined by the Primary Investigator via the medical history, a physical examination, and screening laboratory investigations.
- •A body mass index (BMI) between 18 and
- •Able and willing to give written informed consent prior to participation in the study.
- •A reproducible IPS-induced photo-paroxysmal EEG response (PPR) of at least 3 points on a frequency assessment scale in at least one eye condition and no change of more than 3 frequencies in 2 repeated measurements recorded at the Screening Visit.
排除标准
- •History of non-epileptic seizures (metabolic, structural, or pseudoseizures).
- •History of status epilepticus while on any antiepileptic medication.
- •The etiology of the seizures is due to any of the following; progressive degenerative disease, metabolic illness, active infection, demyelination, drugs, alcohol.
- •The subject has used benzodiazepines (oral, intra-muscular, or suppository) as escape medication within the past 6 months.
- •The subject has taken an investigational medication within 30 days prior to the Day
- •Women who are pregnant or lactating.
- •An active Central Nervous System (CNS) infection, demyelinating disease, degenerative neurological disease or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results.
- •The subject has a clinically significant (e.g., cancerous, unstable, progressive, functionally disabling, or infectious) medical condition that would interfere with the ability to complete the study or that might interfere with the absorption, distribution, metabolism, and/or excretion of drugs.
- •Subjects with impaired hepatic function [ALT (Alanine aminotransferase), AST (Aspartate aminotransferase) =3 times the upper limit of normal] or any clinically significant laboratory abnormality that, in the opinion of the investigator, would increase the risk of participation or interfere with the interpretatio of the study results.
- •History of alcoholism, drug abuse, or drug addiction within the last 12 months.
- •Clinically significant psychiatric illness, psychological or behavioral problem which, in the opinion of the investigator would interfere with the subject's ability to participate in the study OR the subject is receiving therapy with neuroleptic drugs.
- •Subject experiences a clinical seizure during any IPS procedure performed during the screening period.
研究组 & 干预措施
ICA-105665
Experimental
干预措施: ICA-105665 (Drug)
结局指标
主要结局
Change in photosensitivity response
时间窗: begin 1 hr post dose for 8 hours
次要结局
- To correlate plasma concentrations of ICA-105665 with effect on the frequency range of IPS-induced PPR (Photoparoxysmal response) in subjects with photosensitive epilepsy.(3 days)
- To assess the safety of a single dose of ICA-105665 in subjects with photosensitive epilepsy.(30 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
PF-06372865 in Subjects With Photosensitive EpilepsyReflex Epilepsy, PhotosensitiveNCT02564029Pfizer7
已完成
2 期
Effect of Brivaracetam in Photosensitive Epileptic SubjectsEpilepsyNCT00401648UCB Pharma20
终止
1 期
Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive EpilepsyEpilepsyNCT05678881Receptor Life Sciences2
已完成
3 期
SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary GeneralizationEpilepsyNCT00136019UCB Pharma400
已完成
3 期
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary GeneralizationPartial Seizures With or Without Secondary GeneralizationNCT00220415UCB Pharma